HIV Virion Capturing Liposomes for Therapeutic Vaccination

Area of Science:

• Immunology
• Vaccinology
• Nanotechnology

Background:

• HIV infection remains incurable, necessitating lifelong antiretroviral therapy.
• HIV's immune evasion and mutation capabilities hinder effective cure development.
• Current treatments manage viral load but do not eliminate the virus.

Purpose of the Study:

• To introduce a novel therapeutic vaccine strategy for HIV, termed nanotrap therapeutic vaccines (NTVs).
• To design NTVs capable of capturing circulating HIV virions and enhancing antigen presentation.
• To evaluate the immunogenicity and efficacy of NTVs in preclinical models.

Main Methods:

• NTVs were engineered as modified liposomes displaying a CD4 mimetic (CJF-III-288) and containing a TLR 7/8 agonist (R848).
• The capacity of NTVs to bind gp120 and capture pseudoviral particles was assessed.
• Antigen presenting cell uptake and the generation of anti-HIV CD8 T cell responses were evaluated in mouse models.

Main Results:

• NTVs demonstrated effective binding to gp120 and capture of pseudoviral particles.
• Facilitated uptake of NTVs by antigen presenting cells was observed.
• Robust anti-HIV CD8 T cell immunity was generated in transient infection mouse models.

Conclusions:

• NTVs represent a first-in-class therapeutic vaccine approach for HIV.
• The designed NTVs show promise in capturing HIV and stimulating crucial immune responses.
• NTVs hold translational potential for developing patient-specific HIV immunity.